AMT-130 data shows dose-dependent slowing of HD
The clinical researchers argued that the high-dose cohort of AMT-130 showed a statistically significant slowing of Huntington's disease progression compared to an external control group, with a 75% slowing on the primary endpoint and supportive trends across other clinical domains.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.